Study Name: Agitation in Alzheimer's Disease
Clinics: Barnsley, Blackpool, Cannock, Leeds and Manchester
Therapy Area: Alzheimer's Disease
Gender and Age: Male or Female aged 50-90 years old
With an ageing population, medications to help treat the symptoms of Alzheimer’s disease (AD) become more needed than ever. Statistics show that around 80% of patients show signs of agitation and aggression with an increase in prevalence as the disease progresses. Here at MAC, we understand that the condition is incredibly difficult to deal with.
The study being run at MAC research sites in Barnsley, Blackpool, Cannock, Leeds, Liverpool and Manchester is a Phase III, 16-week study to assess a new medication that could help alleviate symptoms of agitation associated with AD. Over the 16-week period, there’ll be a total of 9 visits to a clinic nearest to you and 2 phone calls from a study doctor. The medication itself is currently known as AVP-786. By participating you may be helping to contribute to the development of a new therapy for agitation in AD that may help improve the quality of life for many people.
A full description of the study will be given at the visit before you decide to participate. At that time, you will also receive the full patient information sheet (PIS).
Key Inclusion Criteria:
Men and women aged between 50-90
A diagnosis of Alzheimer’s disease
Symptoms of agitation associated with Alzheimer’s disease
Key Exclusion Criteria:
An uncontrolled or unstable medical condition
Dementia of the non-Alzheimer’s type: vascular, frontotemporal, Parkinson’s etc
Other eligibility criteria will apply. Please contact MAC for more information.
Any other information:
Eligible patients will receive a health screen and study participation will be in collaboration with the patient’s treating physician.
Reasonable travel expenses such as travel by taxi, may be reimbursed. Food may be provided during long study visits if needed.